Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Peptomyc logo — Developing Peptides to treat Cancer

Peptomyc

Developing Peptides to treat Cancer

Founded 2014 Spain Spain 23 employees Total: $49.47M Biotechnology, Health Care +1

General Information

Company Name Peptomyc
Founded Year 2014
Location Spain Spain
Employees 23
Industries Biotechnology, Health Care, Health and Wellness
Business Model B2B, B2B2C, Platform
Revenue Model Licensing, Product Sales, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Peptomyc. To contact Peptomyc, visit peptomyc.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Peptomyc compare?

A PDF of Peptomyc and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Peptomyc soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Oct 27, 2026

Peptomyc management attended the ESMO Congress 2026 in Madrid.

Peptomyc a competitor of yours? Have our desk watch it

About Peptomyc

Peptomyc, with its slogan "Developing Peptides to treat Cancer", is prominently positioned at the intersection of Biotechnology and Health Care. Founded in 2014, this Spain-based company is pioneering a new class of cell-penetrating peptides (CPPs) aimed at targeting the notorious Myc oncoprotein, a formidable contributor to cancer progression.

The company’s foundation stems from over two decades of scientific research spearheaded by Dr. Soucek, focusing on Omomyc, the most effective direct Myc inhibitor thus far. This strong research background equips Peptomyc with a unique competitive edge in the oncological therapeutics space.

In a recent funding round dated 01 June 2023, Peptomyc secured a $2.49M early VC investment from the European Innovation Council. This capital injection not only underscores investor confidence but also brings the company a step closer to revolutionizing cancer treatment.

Business keywords: Cell Penetrating Peptides, Myc Oncoprotein, Cancer Treatment, Omomyc, Drug Development, Oncology, Myc Inhibition, Precision Medicine, Glioblastoma, Non-Small Cell Lung Cancer (NSCLC), Breast Cancer, Cancer Resistance, Novel Therapeutics, VHIO Collaboration

Services & Products

Development of MYC inhibitory drugs
Clinical trial management
Biotechnological research and innovation

Target Customers

Cancer patients with abnormal MYC activity Healthcare providers Oncology research institutions Pharmaceutical partners

Funding Rounds & Investors (13)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC €5.70M 6
Alta Life Sciences Asabys Partners AurorA Science
Alta Life Sciences, Asabys Partners +4
01 Sep 2026
Early VC $2.49M 1
European Innovation Council
European Innovation Council
01 Jun 2023
Late VC €25.00M 4
Alta Life Sciences Healthequity AurorA Science
Alta Life Sciences, Healthequity +2
01 Jan 2022
Late VC €11.40M 4
Alta Life Sciences Healthequity AurorA Science
Alta Life Sciences, Healthequity +2
01 Dec 2020
Grant $2.46M 1
European Commission
01 Jul 2019
Support Program €50.00K 1
Alta Life Sciences
Alta Life Sciences
01 Sep 2017
Grant €210.00K -
01 May 2017
Grant €900.00K 1
EIT Health
01 Jan 2017
Support Program €3.33K 1
EIT Health
01 Oct 2016
Seed €1.00M 1
Riva y Garcia Private Equity
01 May 2016

View All 13 Funding Rounds

Peptomyc Alternatives & Competitors

View All Alternatives
Peptomyc vs
FogPharma
FogPharma United States

Until everything is druggable.

Series E
146 employees
Biopharma, Biotechnology
Peptomyc vs
Incyclix Bio
Incyclix Bio United States

Regaining Cell Cycle Control

Series B
13 employees
Biotechnology, Health Care
Peptomyc vs
Cybrexa Therapeutics
Cybrexa Therapeutics United States

Changing the paradigm for cancer treatment through the development of antigen-independent peptide dr...

Series B
11 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Peptomyc

Developing Peptides to treat Cancer
Peptomyc was founded in 2014.
Peptomyc is headquartered in Spain.
Peptomyc operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Cell Penetrating Peptides, Myc Oncoprotein, Cancer Treatment and Omomyc. Its customers include Cancer patients with abnormal MYC activity, Healthcare providers and Oncology research institutions.
Peptomyc has a B2B, B2B2C and Platform business model. Its revenue comes from Licensing, Product Sales and Performance Based.
Peptomyc has approximately 23 employees.
Peptomyc has completed 13 funding rounds, raising a total of $49.47M.
Peptomyc offers: Development of MYC inhibitory drugs, Clinical trial management, Biotechnological research and innovation.
Top alternatives and competitors to Peptomyc include FogPharma, Incyclix Bio, Cybrexa Therapeutics, Breakpoint Therapeutics, Vicinitas Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Peptomyc and FogPharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Peptomyc, https://bouncewatch.com/company/peptomyc, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout